• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by eFFECTOR Therapeutics Inc. (Amendment)

    2/14/24 9:48:49 AM ET
    $EFTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EFTR alert in real time by email
    SC 13G/A 1 tm246006d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    eFFECTOR Therapeutics, Inc.

    (Name of Issuer)

     

    COMMON STOCK

    (Title of Class of Securities)

     

    28202V108

    (CUSIP Number)

     

    DECEMBER 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.  28202V108 page 2 of 9

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    New Emerging Medical Opportunities Fund III, L.P., an exempted limited partnership

     

    Sectoral GP III, L.P., general partner of New Emerging Medical Opportunities Fund III, L.P

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization :

     

    New Emerging Medical Opportunities Fund III, L.P.: Cayman Islands

     

    Sectoral GP III, L.P.: Canada

     

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power   2,382,644
     
    6. Shared Voting Power   -0-
     
    7. Sole Dispositive Power   2,382,644
     
    8. Shared Dispositive Power   -0-
     

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person   2,382,644
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).   ¨
     
      11. Percent of Class Represented by Amount in Row (9)           3.7%
     
      12. Type of Reporting Person (See Instructions)
        PN

     

     

     

     

    CUSIP No.  28202V108 page 3 of 9

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    Sectoral Asset Management Inc.

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization : Canada
     

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power     2,382,644
     
    6. Shared Voting Power   -0-
     
    7. Sole Dispositive Power  2,382,644
     
    8. Shared Dispositive Power   -0-
     

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person   2,382,644
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).   ¨
     
      11. Percent of Class Represented by Amount in Row (9)           3.7%
     
      12. Type of Reporting Person (See Instructions)
        IA

     

     

     

     

    CUSIP No.  28202V108 page 4 of 9

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    Jérôme G. Pfund

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization : Swiss
     

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power     2,382,644
     
    6. Shared Voting Power   -0-
     
    7. Sole Dispositive Power  2,382,644
     
    8. Shared Dispositive Power   -0-
     

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person   2,382,644
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).   ¨
     
      11. Percent of Class Represented by Amount in Row (9)           3.7%
     
      12. Type of Reporting Person (See Instructions)
        IN

     

     

     

     

    CUSIP No.  28202V108 page 5 of 9

     

    Item 1. (a) Name of Issuer:  
    eFFECTOR Therapeutics, Inc.
         
      (b)

    Address of Issuer's Principal Executive Offices:
    142 North Cedros Avenue, Suite B

    Solana Beach, CA 92075

    USA

     
    Item 2. (a)

    Name of Person(s) Filing:

     

    New Emerging Medical Opportunities Fund III, L.P.

    Sectoral GP III, L.P.

    Sectoral Asset Management Inc.

    Jérôme G. Pfund

      (b)

    Address of Principal Business Office or, if none, Residence:

    The principal business address of each of the Reporting Persons is:
    1610-1010 Sherbrooke St. West, Montreal QC, H3A 2R7 Canada

         
      (c)

    Citizenship:
    New Emerging Medical Opportunities Fund III, L.P is organized under the laws of the Cayman Islands

    Sectoral GP III, L.P. is organized under the laws of Canada

    Sectoral Asset Management Inc. is a Canadian corporation
    Jérôme G. Pfund is a Swiss citizen

      (d) Title of Class of Securities:
    Common Stock
         
      (e) CUSIP Number:
    28202V108
           

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

    CUSIP No.  28202V108 page 6 of 9

     

      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ¨

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________

     

    Item 4. Ownership.

     

     

     

     

    New Emerging Medical Opportunities Fund III, L.P (“Nemo III”) is record owner of 2,382,644 common shares of the Issuer (“Nemo III shares”). Sectoral Asset Management Inc. is the investment adviser of Nemo III, and by virtue of such status may be deemed to be the beneficial owner of the Nemo III shares (240.13d-3(a)). Sectoral Asset Management Inc, in its capacity as investment adviser to Nemo III, has the sole right to dispose of or vote the number of shares of common stock of the Issuer set forth in this filing, and is the owner of the general partner (Sectoral GP III L.P.) of Nemo III. Jérôme G. Pfund indirectly holds majority of shares of Sectoral Asset Management Inc.  

     

      (a)

    Amount beneficially owned:
    New Emerging Medical Opportunities Fund III, L.P.: 2,382,644 shares

    Sectoral GP III, L.P.: 2,382,644 shares

    Sectoral Asset Management Inc.: 2,382,644 shares

    Jérôme G. Pfund: 2,382,644 shares

     

      (b)

    Percent of class:
    New Emerging Medical Opportunities Fund III, L.P.: 3.7%

    Sectoral GP III, L.P.: 3.7%

    Sectoral Asset Management Inc.: 3.7%

    Jérôme G. Pfund: 3.7%

     

      (c) Number of shares as to which the person has:
        (i)

    Sole power to vote or to direct the vote:
    New Emerging Medical Opportunities Fund III, L.P.: 2,382,644 shares

    Sectoral GP III, L.P.: 2,382,644 shares

    Sectoral Asset Management Inc.: 2,382,644 shares

    Jérôme G. Pfund: 2,382,644 shares

     

     

     

     

    CUSIP No.  28202V108 page 7 of 9

     

        (ii) Shared power to vote or to direct the vote:
    Not applicable
        (iii)

    Sole power to dispose or to direct the disposition of:
    New Emerging Medical Opportunities Fund III, L.P.: 2,382,644 shares

    Sectoral GP III, L.P.: 2,382,644 shares

    Sectoral Asset Management Inc.: 2,382,644 shares

    Jérôme G. Pfund: 2,382,644 shares 

        (iv) Shared power to dispose or to direct the disposition of:
    Not applicable.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  x
           
    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    See Item 4.

     
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not applicable.

     
    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable.

     
    Item 10. Certification.
      Not applicable

     

     

     

     

    CUSIP No.  28202V108  page 8 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best knowledge and belief of each of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024 SECTORAL ASSET MANAGEMENT INC.
       

    /s/ Marina Lalakin
       
      By: Maria Lalakin
      Its: Chief Compliance Officer
     
    Dated: February 14, 2024 /s/ Jérôme G. Pfund
      Jérôme G. Pfund
       

     

     

     

     

    CUSIP No.  28202V108 page 9 of 10

     

    Exhibit A

     

    AGREEMENT

     

    Each of the undersigned, pursuant to Rule 13d-1(k)(l) under the Securities Exchange Act of 1934, as amended, hereby agrees that only one statement containing the information required by Schedule 13G needs be filed with respect to the ownership by each of the undersigned of the shares of common stock of eFFECTOR Therapeutics, Inc. and that the Schedule 13G to which this Agreement is appended as Exhibit A is to be filed with the Securities and Exchange Commission on behalf of each of the undersigned on or about the date hereof.

     

    EXECUTED as a sealed instrument this 14th day of February 2024.

     

      SECTORAL ASSET MANAGEMENT INC.
       
      /s/ Marina Lalakin
       
      By: Marina Lalakin
      Its: Chief Compliance Officer
       
      /s/ Jérôme G. Pfund
      Jérôme G. Pfund

     

     

     

    Get the next $EFTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EFTR

    DatePrice TargetRatingAnalyst
    1/25/2022$20.00 → $16.00Outperform
    Credit Suisse
    1/25/2022$20.00 → $6.20Buy → Hold
    Stifel
    1/25/2022$33.00 → $8.00Market Outperform
    JMP Securities
    11/9/2021$20.00Hold → Buy
    Stifel
    10/12/2021$20.00Outperform
    Credit Suisse
    10/4/2021$20.00Buy
    Mizuho
    9/21/2021$33.00Market Outperform
    JMP Securities
    9/20/2021$20.00Hold
    Stifel
    More analyst ratings

    $EFTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse reiterated coverage on eFFECTOR Therapeutics with a new price target

      Credit Suisse reiterated coverage of eFFECTOR Therapeutics with a rating of Outperform and set a new price target of $16.00 from $20.00 previously

      1/25/22 8:03:42 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded eFFECTOR Therapeutics from Buy to Hold and set a new price target of $6.20 from $20.00 previously

      1/25/22 7:56:26 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on eFFECTOR Therapeutics with a new price target

      JMP Securities reiterated coverage of eFFECTOR Therapeutics with a rating of Market Outperform and set a new price target of $8.00 from $33.00 previously

      1/25/22 6:37:05 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    SEC Filings

    See more
    • SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      8/2/24 12:15:03 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      8/2/24 12:15:10 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      8/2/24 12:15:06 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Leadership Updates

    Live Leadership Updates

    See more
    • eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d

      6/24/24 7:00:00 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board's Audit Committee. Concurrent with Ms. Loewy's appointment, current Board member John Smither has resigned from the Board. "We are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies," remarked Steve Worland, Ph.D., president and chief executive office

      9/11/23 8:00:00 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      - Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO – - Cohort treating ER+ breast cancer with combination of zotatifin, fulvestrant and abemaciclib has been expanded from 7 patients to 18 patients - - Initiated dosing and completed enrollment in second cohort of Phase 1b clinical trial of zotatifin for the treatment of COVID-19 - SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended

      11/7/22 4:00:00 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Financials

    Live finance-specific insights

    See more
    • eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

      Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated populationPartial response observed in 1 of 3 (33%) patients treated with zotatifin 0.1 mg/kg combined with fulvestrant (ZF doublet)Both combinations were generally well tolerated with large majority of adverse events Grade 1 or 2Company will host a virtual investor call on June 4, 2023, to discuss the data and clinical progress SOLANA BEACH and REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("

      5/25/23 4:50:54 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023 Company will host conference call to discuss results and further development of zotatifin during ASCO Annual Meeting 2023 Zotatifin is being evaluated in patients with ER+, human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a pre-operative setting through clinical collaboration with Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine SOLANA BEACH and REDWOOD CITY, Calif.

      5/9/23 4:01:00 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced a poster highlighting results from Phase 2 expansion cohorts of a Phase 1/2 dose escalation and expansion trial with zotatifin in patients with ER+ Metastatic Breast Cancer has been selected for presentation at the American Society of Clinical Oncology ("ASCO") 2023 Annual Meeting. Following the presentation, eFFECTOR will host a conference call to discuss the data. The ASCO website indicates that abstracts will be released on May 25, 2023

      4/26/23 4:01:00 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d

      6/24/24 7:00:00 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at

      5/20/24 8:30:00 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

      Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We had a productive first quarter marked by continued progress in the zotatifin program, including successful completion of the

      5/9/24 4:01:00 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Loewy Caroline M

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      6/13/24 6:45:57 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Klencke Barbara

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      6/13/24 6:35:38 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ehrlich Christopher B

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      6/13/24 6:25:33 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by eFFECTOR Therapeutics Inc. (Amendment)

      SC 13D/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      5/13/24 4:05:28 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by eFFECTOR Therapeutics Inc. (Amendment)

      SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      2/14/24 3:48:31 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by eFFECTOR Therapeutics Inc. (Amendment)

      SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      2/14/24 9:48:49 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care